Quest Diagnostics (NYSE:DGX - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 9.550-9.800 for the period, compared to the consensus estimate of 9.720. The company issued revenue guidance of $10.7 billion-$10.9 billion, compared to the consensus revenue estimate of $10.7 billion.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. Mizuho lifted their price objective on Quest Diagnostics from $160.00 to $174.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $185.00 price target (up previously from $175.00) on shares of Quest Diagnostics in a research note on Tuesday, December 10th. Truist Financial increased their price objective on shares of Quest Diagnostics from $158.00 to $165.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. Leerink Partners raised shares of Quest Diagnostics from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $169.00 to $174.00 in a report on Monday, January 6th. Finally, UBS Group lifted their price objective on shares of Quest Diagnostics from $165.00 to $166.00 and gave the company a "neutral" rating in a research note on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Quest Diagnostics currently has a consensus rating of "Moderate Buy" and a consensus target price of $172.15.
Check Out Our Latest Report on Quest Diagnostics
Quest Diagnostics Trading Up 5.5 %
NYSE DGX traded up $8.53 on Thursday, hitting $163.97. The company's stock had a trading volume of 2,601,717 shares, compared to its average volume of 1,024,477. The firm has a market cap of $18.30 billion, a PE ratio of 22.04, a PEG ratio of 2.36 and a beta of 0.90. Quest Diagnostics has a 1-year low of $123.04 and a 1-year high of $167.08. The company's 50-day moving average is $155.42 and its 200 day moving average is $153.43. The company has a quick ratio of 1.17, a current ratio of 1.25 and a debt-to-equity ratio of 0.83.
Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $2.23 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.04. Quest Diagnostics had a return on equity of 15.25% and a net margin of 8.82%. As a group, analysts predict that Quest Diagnostics will post 8.9 earnings per share for the current fiscal year.
Quest Diagnostics Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 21st. Stockholders of record on Monday, April 7th will be given a dividend of $0.80 per share. This is a boost from Quest Diagnostics's previous quarterly dividend of $0.75. This represents a $3.20 annualized dividend and a dividend yield of 1.95%. Quest Diagnostics's dividend payout ratio is 40.32%.
Insiders Place Their Bets
In related news, CAO Michael J. Deppe sold 18,755 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total transaction of $2,889,207.75. Following the transaction, the chief accounting officer now directly owns 34,941 shares of the company's stock, valued at $5,382,661.05. This represents a 34.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.79% of the company's stock.
Quest Diagnostics Company Profile
(
Get Free Report)
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Recommended Stories
Before you consider Quest Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.
While Quest Diagnostics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.